Inhalation, deposition, and fate of insulin and other therapeutic proteins

Diabetes Technology and Therapeutics

Volumn 9, Issue SUPPL. 1, 2007, Pages

  Brain, Joseph D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

BREATHING PATTERN; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; GRAVITY; INSULIN TREATMENT; LUNG CIRCULATION; LUNG DIFFUSION; LUNG PARENCHYMA; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; CILIA; HUMANS; INSULIN; LUNG; MACROPHAGES, ALVEOLAR; METABOLIC CLEARANCE RATE; PROTEINS; PULMONARY CIRCULATION; RESPIRATORY MECHANICS;

EID: 34250741919     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2007.0228     Document Type: Conference Paper

References (35)

1. Brain JD, Blanchard JD: Deposition and fate of inhaled pharmacological aerosols. In: Spector SL, ed. Provocation Testing in Clinical Practice. New York: Marcel Dekker, 1995:157-213.
2. Patton JS, Fishburn CS, Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004;1:338-344.
3. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N: The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2:198-209.
4. Gannslen M: Uber inhalation von insulin. Klin Wochenschr 1925;4:71.
5. Rosenfeld L: Insulin: discovery and controversy. Clin Chem 2002;48:2270-2288.
6. Owens DR, Zinman B, Bolli G: Alternative routes of insulin delivery. Diabet Med 2003;20:886-898.
7. Patton JS, Bukar JG, Eldon MA: Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801.
8. Patton JS, Byron PR: Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007;6:67-74.
9. Mandal TK: Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm 2005;62:1359-1364.
10. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.
11. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): National Diabetes Information Clearinghouse. Bethesda, MD: National Institutes of Heatlh, U.S. Department of Health and Human Services, 2006.
12. Patton JS: Unlocking the opportunity of tight glycaemic control. Innovative delivery of insulin via the lung. Diabetes Obes Metab 2005;7(Suppl 1):S5-S8.
13. Cefalu WT: Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care 2004;27:239-246.
14. Labiris NR, Dolovich MB: Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-599.
15. Cryan SA: Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 2005;7: E20-E41.
16. Otulana B, Okikawa J, Linn L, Morishige R, Thipphawong J: Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. Int J Clin Pharmacol Ther 2004;42:456-462.
17. Suarez S, Hickey AJ: Drug properties affecting aerosol behavior. Respir Care 2000;45:652-666.
18. Cefalu WT: Evaluation of alternative strategies for optimizing glycemia: progress to date. Am J Med 2002; 113(Suppl 6A):23S-35S.
19. Wolff RK: Safety of inhaled proteins for therapeutic use. J Aerosol Med 1998;11:197-219.
20. Frokjaer S, Otzen DE: Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005;4: 298-306.
21. Gonda I: Systemic delivery of drugs to humans via inhalation. J Aerosol Med 2006;19:47-53.
22. Brain JD: Unlocking the opportunity of tight glycaemic control. Inhaled insulin: safety. Diabetes Obes Metab 2005;7(Suppl 1):S14-S18.
23. Tsuda A, Henry FS, Butler JP: Chaotic mixing of alveolated duct flow in rhythmically expanding pulmonary acinus. J Appl Physiol 1995;79:1055-1063.
24. Tsuda A, Rogers RA, Hydon PE, Butler JP: Chaotic mixing deep in the lung. Proc Natl Acad Sci U S A 2002;99:10173-10178.
25. Brain JD, Valberg PA: Deposition of aerosol in the respiratory tract. Am Rev Respir Dis 1979;120:1325-1373.
26. nd ed. Whitehouse Station, NJ: Merck and Co., Inc., 2003.
27. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A: Fundamentals of pulmonary drug delivery. Respir Med 2003;97:382-387.
28. Brain JD: Macrophages in respiratory tract. In: Fishman LAP, ed. Handbook of Physiology. Bethesda, MD: American Physiological Society, 1985:447-471.
29. Ebrahim A, Hamel FG, Bennett RG, Duckworth WC: Identification of the metal associated with the insulin degrading enzyme. Biochem Biophys Res Commun 1991;181:1398-1406.
30. Hamel FG, Bennett RG, Duckworth WC: Regulation of multicatalytic enzyme activity by insulin and the insulin-degrading enzyme. Endocrinology 1998;139: 4061-4066.
31. Bennett RG, Fawcett J, Kruer MC, Duckworth WC, Hamel FG: Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. J Endocrinol 2003;177:399-405.
32. Pfizer: Exubera (Insulin [rDNA Origin] Inhalation Powder) [prescribing information]. Groton, CT: Pfizer, 2006.
33. Labiris NR, Dolovich MB: Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:600-612.
34. Teeter JG, Riese RJ: Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am J Respir Crit Care Med 2006; 173:1194-1200.
35. Jendle JH, Karlberg BE: Intrapulmonary administration of insulin to healthy volunteers. J Intern Med 1996;240:93-98.